Vivos Therapeutics, Inc. (VVOS) stock
VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.08−0.00 (-3.04%)
Close on Nov 17, 2026Market cap $1.60MP/E –Yield –
Vivos Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Vivos Therapeutics's total assets was $24.14M at Jun 30, 2026. For fiscal 2025 it was $25.15M, up 64.6% from the year before. The highest annual figure on record is $33.69M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.15M | +64.6% |
| FY2024 | Dec 31, 2024 | $15.28M | +42.4% |
| FY2023 | Dec 31, 2023 | $10.73M | -21.8% |
| FY2022 | Dec 31, 2022 | $13.72M | -59.3% |
| FY2021 | Dec 31, 2021 | $33.69M | +33.0% |
| FY2020 | Dec 31, 2020 | $25.33M | +235.4% |
| FY2019 | Dec 31, 2019 | $7.55M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $24.14M | -7.3% |
| Q1 FY2026 | Mar 31, 2026 | $25.04M | +122.0% |
| Q4 FY2025 | Dec 31, 2025 | $25.15M | +64.6% |
| Q3 FY2025 | Sep 30, 2025 | $25.64M | +67.1% |
| Q2 FY2025 | Jun 30, 2025 | $26.03M | +64.3% |
| Q1 FY2025 | Mar 31, 2025 | $11.28M | -4.4% |
| Q4 FY2024 | Dec 31, 2024 | $15.28M | +42.4% |
| Q3 FY2024 | Sep 30, 2024 | $15.35M | +48.8% |
| Q2 FY2024 | Jun 30, 2024 | $15.84M | +15.2% |
| Q1 FY2024 | Mar 31, 2024 | $11.80M | -31.0% |
| Q4 FY2023 | Dec 31, 2023 | $10.73M | -21.8% |
| Q3 FY2023 | Sep 30, 2023 | $10.32M | -43.9% |
| Q2 FY2023 | Jun 30, 2023 | $13.75M | -43.6% |
| Q1 FY2023 | Mar 31, 2023 | $17.10M | -42.1% |
| Q4 FY2022 | Dec 31, 2022 | $13.72M | -59.3% |
| Q3 FY2022 | Sep 30, 2022 | $18.40M | -55.1% |
| Q2 FY2022 | Jun 30, 2022 | $24.38M | -47.2% |
| Q1 FY2022 | Mar 31, 2022 | $29.56M | +34.6% |
| Q4 FY2021 | Dec 31, 2021 | $33.69M | +33.0% |
| Q3 FY2021 | Sep 30, 2021 | $41.02M | +443.3% |
| Q2 FY2021 | Jun 30, 2021 | $46.16M | – |
| Q1 FY2021 | Mar 31, 2021 | $21.95M | – |
| Q4 FY2020 | Dec 31, 2020 | $25.33M | – |
| Q4 FY2019 | Dec 31, 2019 | $7.55M | – |
See a number that looks wrong?